- New project aims to speed up process of finding treatments for chronic obstructive pulmonary disease (COPD), asthma and pulmonary fibrosis
- Scientists at the University of Leicester, University of Nottingham and University of Cambridge, will connect data science, genomics and laboratory research for the first time in tackling lung conditions
- New genetic markers of lung function to be identified, which will provide new targets for drug development
- Chronic respiratory disease, such as COPD, is the third leading cause of death globally
Patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) and a history of frequent ‘attacks’ who were given a medicine called astegolimab reported an increase in health-related quality of life compared to those on a placebo, according to findings from a study published in the Lancet Respiratory Medicine.
More than 1 in 10 people worldwide have chronic obstructive pulmonary disease (COPD) and many more remain undiagnosed. Most people with COPD live in low- and middle-income countries (LMICs). One of the best ways to help people manage the symptoms and consequences of their COPD is Pulmonary Rehabilitation.Read More
Researchers at the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (BRC) – a partnership between the University of Leicester, Leicester’s Hospitals and Loughborough University – have found that a widely used 8 point questionnaire for COPD and other respiratory conditions may be a useful tool for assessing people’s health during COVID-19 recovery.Read More
An international team of scientists, led by the Universities of Leicester and Glasgow, has announced findings that could pave the way to a new treatment for asthma and chronic obstructive pulmonary disease (COPD).Read More